齐拉西酮对首发精神分裂症患者认知功能的影响

目的探讨齐拉西酮和氯丙嗪对首发精神分裂症患者认知功能的影响。方法将符合入组标准的首发精神分裂症86例随机分为齐拉西酮组与氯丙嗪组,分别进行8周的系统治疗,使用阳性与阴性症状量表(PANSS)评定疗效,治疗时出现的症状量表(TESS)评定不良反应,韦氏成人智力量表(WAISR)、韦氏记忆量表(WMS)和威斯康星卡片分类测验(WCST)评定治疗前后患者认知功能的改变。结果治疗后86例PAN-SS总分明显下降,两组之间差异无显著性(均P>0.05);齐拉西酮不良反应较氯丙嗪少,治疗前两组患者均有认知功能损害,治疗8周后,齐拉西酮组患者的认知功能有明显提高,而氯丙嗪组则无明显改善。结论齐拉西酮治疗精神分裂症疗效与氯丙嗪相当,且不良反应小,在改善认知功能方面优于氯丙嗪。

A comparison analysis on the efficacy of ziprasidone in cognitive function of first-episode schizophrenia

Objective To compare the effect of ziprasidone and chlorpromazine on the efficacy and cognitive function in first - episode schizophrenia. Methods 86 patients with schizophrenia were randomly treated with ziprasidone and chlorpremazine for 8 weeks. The therapeutic response was evaluated with the PANSS and treatment emergent symptoms scale （TESS） were used to evaluate the effcacy. With the Wechsler adult intelligence scale （WAISR）, Wechsler menory scale （WMS） and Wisconsin card sorting test（WCST） assessment of cognitive function in patients before and after treatment changes. Results 86 patients after treatment, PANSS total score decreased significantly, no significant difference between the two groups （ P 〉 0. 05 ） ; Fewer side effects than chlorpromazine ziprasidone. Before treatment,two groups of patients had cognitive impairment. After 8 weeks, ziprasi- done group were significantly improved cognitive function,hut no significant improvement of ehlorpromazine group. Conclusion The efficacy of ziprasidone and chlorpromazine in the treatment of schizophrenia rather, side effects, is superior in improving the cognitive function of chiorpremazine.